Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

President Donald Trump says he'll sign an executive order on Monday that, if implemented, could bring down the costs of some ...

A Milwaukee apartment building fire that began in a common area and spread to multiple floors Sunday killed four people and ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Lilly is already stocking $550 million in pre-launch inventory to prevent the sort of shortages that plagued its rollout of Mounjaro and Zepbound, Orforglipron complements Mounjaro ...

and Zepbound, which treats obesity. Compound medicine providers were allowed to make and distribute copycat versions of tirzepatide injection products until December 2024, when the FDA issued a ...

Eli Lilly has gone through a similar legal process with tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro. The FDA declared the U.S. shortage of ...

Pharmaceutical companies like Novo Nordisk and Eli Lilly took the world by storm last year with a new generation of so-called GLP-1 diet products - Ozempic, Wegovy and Zepbound. The drugs were ...

It also follows a decision the judge made earlier this year refusing to allow compounding pharmacies to keep making copies of Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro.

Despite broader market uncertainties, the company’s robust performance in the diabetes and obesity segments, particularly with GLP-1 drugs like Mounjaro and Zepbound, has bolstered analysts ...